GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Ortho Clinical Diagnostics Holdings PLC (NAS:OCDX) » Definitions » EBITDA per Share

Ortho Clinical Diagnostics Holdings (Ortho Clinical Diagnostics Holdings) EBITDA per Share : $1.93 (TTM As of Mar. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Ortho Clinical Diagnostics Holdings EBITDA per Share?

Ortho Clinical Diagnostics Holdings's EBITDA per Share for the three months ended in Mar. 2022 was $0.53. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $1.93.

During the past 12 months, the average EBITDA per Share Growth Rate of Ortho Clinical Diagnostics Holdings was 21.70% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Ortho Clinical Diagnostics Holdings's EBITDA per Share or its related term are showing as below:

OCDX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -18   Med: -6.4   Max: 5.2
Current: 5.2

During the past 5 years, the highest 3-Year average EBITDA per Share Growth Rate of Ortho Clinical Diagnostics Holdings was 5.20% per year. The lowest was -18.00% per year. And the median was -6.40% per year.

OCDX's 3-Year EBITDA Growth Rate is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 2.3 vs OCDX: 5.20

Ortho Clinical Diagnostics Holdings's EBITDA for the three months ended in Mar. 2022 was $129 Mil.

During the past 12 months, the average EBITDA Growth Rate of Ortho Clinical Diagnostics Holdings was 30.70% per year. During the past 3 years, the average EBITDA Growth Rate was 6.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 5 years, the highest 3-Year average EBITDA Growth Rate of Ortho Clinical Diagnostics Holdings was 6.10% per year. The lowest was -18.60% per year. And the median was -6.25% per year.


Ortho Clinical Diagnostics Holdings EBITDA per Share Historical Data

The historical data trend for Ortho Clinical Diagnostics Holdings's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ortho Clinical Diagnostics Holdings EBITDA per Share Chart

Ortho Clinical Diagnostics Holdings Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21
EBITDA per Share
2.44 1.56 1.69 1.35 1.82

Ortho Clinical Diagnostics Holdings Quarterly Data
Dec17 Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.47 0.58 0.35 0.53

Ortho Clinical Diagnostics Holdings EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Ortho Clinical Diagnostics Holdings's EBITDA per Share for the fiscal year that ended in Dec. 2021 is calculated as

EBITDA per Share(A: Dec. 2021 )
=EBITDA/Shares Outstanding (Diluted Average)
=415.1/228.200
=1.82

Ortho Clinical Diagnostics Holdings's EBITDA per Share for the quarter that ended in Mar. 2022 is calculated as

EBITDA per Share(Q: Mar. 2022 )
=EBITDA/Shares Outstanding (Diluted Average)
=128.6/242.000
=0.53

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ortho Clinical Diagnostics Holdings  (NAS:OCDX) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Ortho Clinical Diagnostics Holdings EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Ortho Clinical Diagnostics Holdings's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Ortho Clinical Diagnostics Holdings (Ortho Clinical Diagnostics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
1001 Route 202, Raritan, NJ, USA, 08869
Ortho Clinical Diagnostics Holdings PLC offers in vitro diagnostics solutions and services. It provides diagnostic testing solutions to the clinical laboratory and transfusion medicine communities. The company operates through three geographic segments such as Americas, EMEA, Greater China, and Other. Americas segment generates most of the revenue for the firm.
Executives
Robert Clifton Yates director C/O ORTHO CLINICAL DIAGNOSTICS HOLDINGS 1001 ROUTE 202 RARITAN NJ 08869
Chockalingam Palaniappan officer: Chief Innovation Officer C/O ORTHO CLINICAL DIAGNOSTICS HOLDINGS 1001 ROUTE 202 RARITAN NJ 08869
Christopher M Smith director, officer: Chairman and CEO 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Michael S. Iskra officer: Executive Vice President C/O ORTHO CLINICAL DIAGNOSTICS HOLDINGS, 1001 ROUTE 202, RARITAN NJ 08869
Joseph M Busky officer: Chief Financial Officer 1717 DEERFIELD ROAD, DEERFIELD IL 60015
Michael A. Schlesinger officer: EVP, GC and Secretary C/O ORTHO CLINICAL DIAGNOSTICS HOLDINGS 1001 ROUTE 202 RARITAN NJ 08869
Carlyle Partners Vi Cayman Holdings, L.p. 10 percent owner C/O WALKERS CORPORATE LIMITED, CAYMAN CORPORATE CENTRE, 27 HOSPITAL RD., GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Tc Group Vi Cayman, L.l.c. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Tc Group Vi Cayman, L.p. 10 percent owner C/O WALKERS CORPORATE LIMITED, CAYMAN CORPORATE CENTRE, 27 HOSPITAL RD., GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Cg Subsidiary Holdings L.l.c. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Tc Group Cayman Investment Holdings Sub L.p. 10 percent owner C/O WALKER CORPORATE SERVICES LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9001
Carlyle Holdings Ii L.l.c. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings Ii Gp L.l.c. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Tc Group Cayman Investment Holdings, L.p. 10 percent owner C/O WALKERS CORPORATE SERVICES LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9001

Ortho Clinical Diagnostics Holdings (Ortho Clinical Diagnostics Holdings) Headlines